Tokyo-based biotech firm PeptiDream and Kleo Pharmaceuticals, of Connecticut, USA, have reached a deal to co-develop immuno-oncology products in multiple indications.
Kleo uses its Antibody Recruiting Molecule (ARM) and Synthetic Antibody Mimic (SyAM) technologies to develop small-molecule immunotherapies.
Under the terms of the agreement, PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to identify certain peptides against multiple oncology targets of interest, selected by Kleo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze